Instil Bio Enrollment of 1L NSCLC patients in China trial of AXN-2510/IMM2510 in combination with chemotherapy is ongoing with initial clinical data by ImmuneOnco expected in 2H 2025 Initiation of U.S. clinical study of AXN-2510/IMM2510 in combination with chemotherapy in 1L NSCLC anticipated before the end of 2025, assuming receipt of necessary regulatory approvals DALLAS,
Financial Outlook For the full year 2025, Spire expects Spire platform / infrastructure capital expenditures to range between $8.0 and $10.0 million. Spire is providing the following guidance for the second quarter 2025 and full year ending December 31, 2025: Q2’25 Ranges FY’25 Ranges Low High Low High Revenue (millions) $ 18.0 $ 20.0
__________________ 1 Cost of sales per ounce of gold sold represents total cost of sales for Chelopech and Ada Tepe, divided by total payable gold in concentrate sold, while all-in sustaining cost per ounce of gold sold includes treatment and freight charges, net of by-product credits, all of which are reflected in revenue. 2 All-in
Financial Outlook We are providing estimates for the second quarter and full year 2025 based on current market conditions and expectations. The revenue growth rates are adjusted for constant currency to provide better visibility into the underlying business trends. We emphasize that these estimates are subject to various important cautionary factors referenced in the section
GROUPE BRUXELLES LAMBERT (GBL) GBL reported a net asset value 5 of €15.7 billion or €113.30 per share at December 31, 2024, compared with €16.7 billion or €113.64 per share at December 31, 2023. In 2024, GBL completed €292 million of share buybacks, and cancelled 8.3 million treasury shares. SAGARD HOLDINGS INC. (SAGARD) On March
PITTSBURGH, Feb. 27, 2025 /PRNewswire/ — Viatris Inc. (Nasdaq: VTRS) today announced strong financial results for the fourth quarter and full year 2024—including divestiture-adjusted operational revenue growth of 2% for the full year with growth across all segments, new product revenues of $582 million and full year free cash flow that exceeded the Company’s guidance.[2] “2024
MILPITAS, Calif., February 19, 2025–(BUSINESS WIRE)–SolarEdge Technologies, Inc. (Nasdaq: SEDG), a global leader in smart energy technology, today announced its financial results for the fourth quarter ended December 31, 2024 and full year ended December 31, 2024. “There are exciting opportunities ahead for SolarEdge,” said Shuki Nir, CEO of SolarEdge. “We are just getting started